Cytokine regulation of CD44 expression on rat intestinal epithelial cells.
CD44 comprises a family of type I transmembrane glycoproteins that is expressed on a wide range of cells including those of epithelial, lymphoid and myeloid lineage. Although expression of CD44 in the small intestine is typically localised in the crypts of Lieberkuhn, we have reported the expression of CD44 on mature, intestinal villus epithelial cells during the development of small bowel allograft rejection. The mechanisms underlying CD44 up-regulation are unknown, although it may be influenced by localised cytokine production. This study used flow cytometry to assess the effects of recombinant IFN-gamma and TNF-alpha on CD44 expression and hyaluronan binding by the rat small intestinal epithelial cell lines, RIE and IEC 6. IFN-gamma upregulated CD44 expression on RIE (155% of unstimulated control) and IEC 6 (209% of unstimulated control) cells, whereas TNF-alpha had no effect. IFN-gamma had no qualitative effect on CD44, as binding of the ubiquitously expressed extracellular matrix polysaccharide hyaluronan was unchanged. RIE and IEC 6 cells expressed the 82 kDa and 130 kDa major isoforms of CD44, however cytokine stimulation did not affect the expression of these, nor did stimulation induce the expression of other variants. In summary, these findings demonstrate that CD44 expression by intestinal epithelial cells can be regulated by cytokines, yet their ability to bind hyaluronan and the isoform of the expressed CD44 remains unaltered. It appears that localised inflammatory conditions and cytokine production may modify epithelial cell expression of CD44, however the physiological role for such a response has yet to be elucidated.
Division of Clinical Sciences NGH, Clinical Sciences Centre, Northern General Hospital, Sheffield, UK.
S D
SD
Reid
A G
AG
Pockley
D017398:Alternative Splicing; D000818:Animals; D004347:Drug Interactions; D006031:Glycosylation; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D006820:Hyaluronic Acid / Q000378:metabolism; D018836:Inflammation Mediators / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000166:cytology / Q000187:drug effects*; D007421:Intestine, Small / Q000166:cytology / Q000187:drug effects*; D011485:Protein Binding; D020033:Protein Isoforms / Q000096:biosynthesis; D011499:Protein Processing, Post-Translational; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D015395:Histocompatibility Antigens Class I; D018960:Hyaluronan Receptors; D018836:Inflammation Mediators; D020033:Protein Isoforms; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D006820:Hyaluronic Acid